<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315144</url>
  </required_header>
  <id_info>
    <org_study_id>TV48108-COPD-10045</org_study_id>
    <nct_id>NCT02315144</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients</brief_title>
  <official_title>A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to characterize the safety profile and duration of
      bronchodilation of a single dose of inhaled TV48108.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline adjusted forced expiratory volume in 1 second area under the curve over 12 hours (FEV1 AUC0-12h).</measure>
    <time_frame>Day 1 (pre-dose, up to 12 hours post-dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Adjusted Trough 12 hour forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Day 1 (pre-dose, up to 12 hours post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>TV48108 - Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1 is a randomized, placebo-controlled, double-blind, single-dose study. Healthy subjects will be randomized to receive a single inhaled dose of TV48108 120 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Healthy Volunteers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV48108 15 µg COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2 consists of a 2-period open-label study with an ipratropium bromide reference to evaluate the single administration of 3 ascending doses of inhaled TV48108 in COPD patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV48108 60 µg COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV48108 120 µg COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2 .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV48108</intervention_name>
    <description>TV48108 15, 60, 120 μg</description>
    <arm_group_label>TV48108 - Healthy Volunteers</arm_group_label>
    <arm_group_label>TV48108 15 µg COPD</arm_group_label>
    <arm_group_label>TV48108 60 µg COPD</arm_group_label>
    <arm_group_label>TV48108 120 µg COPD</arm_group_label>
    <other_name>48108</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo - Healthy Volunteers</arm_group_label>
    <other_name>Matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Stage 1 (Healthy Volunteers)

          -  Male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg with a body mass
             index (BMI) of less than 30 kg/m^2.

          -  In good health as determined by medical and psychiatric history, physical examination,
             electrocardiogram (ECG), serum chemistry, hematology, urinalysis, and serology.

          -  Other criteria apply, please contact the investigator for more information

        Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)

          -  Male or female; 40 to 75 years of age, inclusive with a minimum body weight of 40 kg

          -  Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack
             years at the screening visit

          -  Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung
             Disease guidelines.

          -  Other criteria apply, please contact the investigator for more information

        Exclusion Criteria:

        Stage 1 (Healthy Volunteers)

          -  History or current evidence of a clinically significant or uncontrolled disease

          -  Any disorder that may interfere with the absorption, distribution, metabolism or
             excretion of study drugs.

          -  History of severe allergy to milk protein

          -  Active smokers or former smokers who quit within 3 months of the first dose of study
             drug. Former smokers with greater than five-pack years (ie, the equivalent of one pack
             per day for five years) are also excluded.

          -  Other criteria apply, please contact the investigator for more information

        Stage 2 (Chronic Obstructive Lung Disease (COPD) patients)

          -  Recent history of hospitalization due to an exacerbation of airway disease within 3
             months

          -  Need for increased treatments of COPD within 6 weeks prior to the screening visit

          -  History of and/or current diagnosis of asthma

          -  Known α1 antitrypsin deficiency, active lung infections (such as tuberculosis or
             pneumonia), and lung cancer are absolute exclusionary conditions

          -  Other criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 13038</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13039</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78992</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78993</name>
      <address>
        <city>Daws Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 78991</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 79041</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 79040</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>bronchodilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

